14006-31-6

Basic information

• Product Name: (4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl)
• Synonyms: (4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl);Tetrahydro-4-phenyl-2H-pyran-4-aMine;4-phenyloxan-4-amine
• CAS NO: 14006-31-6
• Molecular Formula: C₁₁H₁₅NO
• Molecular Weight: 177.2429
• Mol File: 14006-31-6.mol

Chemical Properties

• Boiling Point: 284.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.056±0.06 g/cm3(Predicted)
• PKA: 8.75±0.20(Predicted)
• CAS DataBase Reference: (4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: (4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl)(14006-31-6)
• EPA Substance Registry System: (4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl)(14006-31-6)

Safety Data

• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 14006-31-6(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
(4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl) is used as a chemical intermediate for the synthesis of various complex organic molecules. Its unique structure allows it to be a versatile building block in the creation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
(4-phenyltetrahydro-2H-pyran-4-yl)amine(SALTDATA: HCl) is used as a potential active pharmaceutical ingredient (API) for the development of new drugs. Its amine functionality and pyran ring system may contribute to its interaction with biological targets, such as enzymes or receptors, making it a candidate for therapeutic applications in various diseases.

Upstream product

• 1202-81-9 4-phenyltetrahydro-2H-pyran-4-carbonitrile 
• 140-29-4 phenylacetonitrile 
• 939801-34-0 C₁₃H₁₇NO₂ 

Downstream Products

• 939801-35-1 C₂₆H₃₃FN₂O₄ 

Relevant articles and documents

Synthesis method of six-membered ring benzylamine compound

The invention relates to the field of synthesis of organic matters, and particularly discloses a synthesis method of a six-membered ring benzylamine compound, which comprises the following steps: taking a compound D, a compound E and potassium tert-butoxide as raw materials, taking dimethyl sulfoxide as a solvent, reacting at 5-10 DEG C for 1-2 hours, heating to 20 DEG C, reacting, and purifying and separating after the reaction is finished to obtain a compound A; the method comprises the following steps: by taking a compound A, potassium carbonate and hydrogen peroxide as raw materials and dimethyl sulfoxide as a solvent, reacting at 50-65 DEG C, adding ice water to separate out a product after the reaction is finished, filtering and washing to obtain a compound B; dissolving the compound B in acetonitrile, adjusting the pH value to 13-14, adding a saturated sodium hypochlorite solution for reaction, and purifying and washing after the reaction is finished to obtain a compound C; the method has the effect of improving the defect that the synthesis process of the six-membered ring benzylamine compound is not suitable for industrial production.

(3R)-3-Amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides and 3-amino-N-(4-aryltetrahydropyran-4-yl)butanamides were synthesized and evaluated as dipeptidyl peptidase IV (DPP-IV) inhibitors. Derivatives incorporating the 6-substituted benzothiazole group showed highly potent DPP-IV inhibitory activity. Oral administration of (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide (12u) reduced blood glucose excursion in an oral glucose tolerance test.